Patents Examined by Kristin Vajda
  • Patent number: 11684603
    Abstract: Disclosed are methods for ameliorating glycocalyx damage by administering a neuraminidase inhibitor. Also disclosed are methods for treating endothelial dysfunction and for improving flow mediated dilation.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: June 27, 2023
    Assignee: CURATORS OF THE UNIVERSITY OF MISSOURI UNIVERSITY
    Inventors: Luis A. Martinez-Lemus, Christopher A. Foote, Jaume Padilla
  • Patent number: 11680073
    Abstract: Disclosed are compounds for medical uses, for example, compounds of formula Ia, wherein A1, A2, A3, A4, A5, A6, A7, R6, R7 and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: June 20, 2023
    Assignee: ADT PHARMACEUTICALS, LLC
    Inventors: Michael Boyd, Xi Chen
  • Patent number: 11680069
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: September 23, 2022
    Date of Patent: June 20, 2023
    Assignee: AbbVie Inc.
    Inventors: Ayman Allian, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Thomas B. Borchardt
  • Patent number: 11673855
    Abstract: Provided herein are radiolabeled compounds useful for minimally invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for position emission tomography imaging of voltage gated sodium channels. Methods for prepared unlabeled and labeled compounds, and diagnostic methods using the compounds are also provided.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: June 13, 2023
    Assignee: The General Hospital Corporation
    Inventors: Matthias Schoenberger, Jacob Hooker
  • Patent number: 11673886
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: June 13, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter W. Glunz, Vladimir Ladziata, Indawati De Lucca, George O. Tora, Tarun Kumar Maishal, Raghuram Tangirala, Kamalraj Thiyagarajan
  • Patent number: 11667658
    Abstract: The subject invention provides methods for the chemical synthesis of racemic arsinothricin (D,L-AST), the novel organoarsenical antibiotic. One is by condensation of the 2-chloroethyl(methyl)arsinic acid with acetamidomalonate, and the second involves reduction of the N-acetyl-protected derivative of hydroxyarsinothricin (AST-OH) and subsequent methylation of the resulting sodium salt of trivalent arsenic intermediate with methyl iodide. The enzyme AST N-acetyltransferase (ArsN1) was utilized to purify L-AST from racemic AST. This expedient chemical synthesis of AST provides a source of this novel antibiotic for future drug development.
    Type: Grant
    Filed: December 5, 2022
    Date of Patent: June 6, 2023
    Assignee: The Florida International University Board of Trustees
    Inventors: Barry P. Rosen, Masafumi Yoshinaga, Stanislaw F. Wnuk, Md Abu Hasan Howlader, Sk Md Sazzad Hossain Suzol
  • Patent number: 11666551
    Abstract: An object of the present invention is to provide a drug and a method which suppress progress of disease in which the amount of amyloid ? protein in the brain is increased, such as Alzheimer's disease. 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of reducing the amount of amyloid ? protein in the brain parenchyma, and thus is effective as an agent for reducing the amount of amyloid ? protein in the brain. Disease in which the amount of amyloid ? protein in the brain is increased, such as Alzheimer's disease, can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: June 6, 2023
    Assignee: FUJIFILM Toyama Chemical Co., Ltd.
    Inventors: Hiroshi Kobayashi, Yoshihiko Matsumoto
  • Patent number: 11667655
    Abstract: Silicon-based tetrahydrocannabinol derivatives and methods for their synthesis are provided, in which the derivatives contain a tetrahydrocannabinol molecule and at least one silicon-based group containing Si—O—Si bonds. The derivatives are useful in topical and dermatological compositions, have potential beneficial topical properties, and enhance solubility and compatibility in topical and dermatological formulations containing the silicon-based materials.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: June 6, 2023
    Assignee: GELEST, INC.
    Inventors: Barry C. Arkles, Taewoo Min, Jonathan D. Goff
  • Patent number: 11666631
    Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: June 6, 2023
    Assignee: Arch Biopartners, Inc.
    Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing Sze Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
  • Patent number: 11660342
    Abstract: The present invention relates to a method for increasing the blood-brain barrier permeability, and more particularly, to a method for increasing the blood-brain barrier permeability, the method including: (S1) a step of delivering a nanogenerator carrying a nitric oxide (NO) donor to a site adjacent to the blood-brain barrier; (S2) a step of delivering a first triggering stimulus to an area where the nanogenerator has been delivered so as to release nitric oxide from the nanogenerator; and (S3) a step of allowing the released nitric oxide to activate matrix metallopeptidase-9 (MMP-9) and inducing the activated MMP-9 to weaken the tight junction between a cerebrovascular endothelial cell and another cerebrovascular endothelial cell.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: May 30, 2023
    Assignee: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION
    Inventors: Won Jong Kim, Taejeong Kim
  • Patent number: 11661425
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: September 23, 2022
    Date of Patent: May 30, 2023
    Assignee: AbbVie Inc.
    Inventors: Ayman Allian, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Thomas B. Borchardt
  • Patent number: 11655230
    Abstract: The invention relates to a process for producing ethylene glycol and/or ethylene carbonate, said process comprising contacting at least a portion of a recycle gas stream comprising an alkyl iodide impurity with a guard bed system positioned upstream of an ethylene oxide reactor to produce a treated recycle gas stream, wherein the guard bed system comprises silver on alumina; contacting a feed gas stream comprising ethylene, oxygen and at least a portion of the treated recycle gas stream with an epoxidation catalyst in the ethylene oxide reactor to produce an epoxidation reaction product comprising ethylene oxide; and contacting at least a portion of the epoxidation reaction product comprising ethylene oxide with an aqueous absorbent in the presence of an iodide-containing catalyst in an absorber to produce an aqueous product stream comprising ethylene carbonate and/or ethylene glycol and the recycle gas stream comprising the alkyl iodide impurity.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: May 23, 2023
    Assignee: SHELL USA, INC.
    Inventors: Roel Guillaume Hubertus Leonardus Bastings, Jesse Raymond Black, Vesna Bojovic, Wayne Errol Evans
  • Patent number: 11649415
    Abstract: The present invention relates to a composition comprising a) at least one oil phase, b) at least one aqueous phase, c) at-least one emulsifier, wherein the at-least one emulsifier is any or combination of at-least one emulsifier agent, water with emulsification properties, oil with emulsification properties, and active ingredient with emulsification properties; and d) optionally, one or more biologically active ingredients. The present invention also relates to use of the composition for personal care, pet care, home care, deodorants, pesticides, moisturizers, disinfectants, cleansers, therapeutic devices, topical supplements and/or nutrition. The present invention also relates to a method for preparing such a composition.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: May 16, 2023
    Inventor: Reza Fatahi
  • Patent number: 11649215
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: May 16, 2023
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Patent number: 11642308
    Abstract: Disclosed herein is a ready-to-use liquid, injectable formulation comprising lidocaine and epinephrine. Also disclosed herein is a process for preparing a ready-to-use liquid formulation comprising lidocaine and epinephrine, as well as methods for using the ready-to-use liquid formulation.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: May 9, 2023
    Assignee: QUVA PHARMA, INC.
    Inventors: Travis A. Leeah, Jianping Chen, Lijie Zhao
  • Patent number: 11643423
    Abstract: The subject invention provides catalytical compounds/complexes, compositions comprising such compound/complex, synthesis of the compounds/complexes, and methods of using such compounds/complexes as catalysts in, for example, RCM reactions. Specifically, the subject invention provides the synthesis of the first catalytically active V oxo alkylidene, VO(CHSiMe3)(PEt3)2Cl, which exhibits superior performance compared to other analogs.
    Type: Grant
    Filed: August 9, 2022
    Date of Patent: May 9, 2023
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Konstantin Bukhryakov, Dmitry Belov
  • Patent number: 11633353
    Abstract: The invention provides an aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), the solution comprising at least 5 mg/ml dissolved levodopa, and having a pH in the range of 3.0 to 8.5. Said solution is provided by mixing a) an aqueous stock solution comprising levodopa, said stock solution having a pH of less than 2.8 at 25° C. and b) an aqueous buffering solution, for increasing the pH of said stock solution, said buffering solution having a pH of at least 4.0 at 25° C. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the central nervous system (CNS) shortly after mixing of the aqueous stock solution and the aqueous buffering solution. Furthermore, the invention provides a kit for administration of aqueous pharmaceutical solutions to subjects suffering from diseases of the central nervous system (CNS).
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: April 25, 2023
    Assignee: DIZLIN PHARMACEUTICALS AB
    Inventors: Elias Eriksson, Nil Dizdar Segrell, Mats Ehrnebo, Leif Bring
  • Patent number: 11623919
    Abstract: Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions containing them, and to a process for the preparation of the compounds: R1 is independently selected from hydrogen atom, amine group, monocyclic or bicyclic aliphatic, aromatic, heteroaliphatic or heteroaromatic ring. R2 is independently selected from monocyclic or bicylic aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, C1-C6 alkyl, alkenyl or alkynyl chain. n is 1 or 2; preferably n is 1. m is 0, 1 or 2; preferably m is 0. R3 and R4 can be, independently, —H, —F, C1-C4 alkyl, —OH, —OC1-C4 alkyl; preferably they are both —H. X is O or S. R5 is —H or —CH3 optionally substituted by one or more fluorine atoms; preferably R5 is hydrogen. The compounds can be used in the treatment of conditions or diseases mediated by P2X7 receptor.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: April 11, 2023
    Assignee: BREYE THERAPEUTICS APS
    Inventors: Paolo Pevarello, Mariangela Sodano, Elda Severi, Rocco Vitalone, Russell Thomas, Valentina Cusano
  • Patent number: 11618747
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: April 4, 2023
    Assignee: OrsoBio, Inc.
    Inventors: Christian Gege, Olaf Kinzel, Eva Hambruch, Manfred Birkel, Claus Kremoser, Ulrich Deuschle
  • Patent number: 11613542
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with a nitrogen-containing group R1? wherein R1 contains from 1 to 7 atoms other than hydrogen or halogen. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: March 28, 2023
    Assignee: Inflazome Limited
    Inventors: Matthew Cooper, David Miller, Angus Macleod, Stephen Thom, Stephen St-Gallay, Jonathan Shannon, Thomas Alanine, Stuart Onions, Ian Strutt, Jokin Carrillo Arregui